Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
    • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Clinical practice
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    The Case of the Post-Transplant Pulmonary Problem
    Clinical practice
    The Case of the Post-Transplant Pulmonary Problem
    January 14, 2022
    How Nurses Can Monitor and Strengthen Their Mental Health
    Nurse well-being
    How Nurses Can Monitor and Strengthen Their Mental Health
    December 17, 2021
    Nurses Must Take the Lead in Tobacco Cessation
    Cancer risk factors
    Nurses Must Take the Lead in Tobacco Cessation
    November 26, 2021
    Exercise the Evidence: How I Moved From an Idea to Program Development
    Patient quality of life
    Exercise the Evidence: How I Moved From an Idea to Program Development
    November 19, 2021
    The Case of the Missing Oral Mucositis
    Radiation therapy
    The Case of the Missing Oral Mucositis
    October 22, 2021
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
    • Home

    Author Content

    Diagnose and Treat Hypercalcemia of Malignancy
    Advanced practice nursing (APN)

    Diagnose and Treat Hypercalcemia of Malignancy

    Hypercalcemia of malignancy (HCM) is a common paraneoplastic syndrome associated with poor prognosis that affects approximately 20%–30% of patients with cancer. It’s most often seen in patients with breast, lung, renal, or ovarian cancers; squamous cell carcinoma of the head and neck; multiple myeloma; and certain lymphomas.

    July 15, 2021
    Targeted Therapies Are Transforming the Treatment of Non-Small Cell Lung Cancer
    Lung Cancer

    Targeted Therapies Are Transforming the Treatment of Non-Small Cell Lung Cancer

    Testing for molecular biomarkers has become a mainstay in determining treatment approaches for advanced-stage non-small cell lung cancer. Typically, next-generation sequencing identifies any potential genomic variants that are associated with oncogenic driver events and can be targeted with oral tyrosine kinase inhibitors.

    May 17, 2021
    Management Strategies for Cutaneous Toxicity From EGFR Inhibitors
    Advanced practice nursing (APN)

    Management Strategies for Cutaneous Toxicity From EGFR Inhibitors

    Epidermal growth factor receptor (EGFR)-targeted therapy is effective for several solid tumor malignancies, primarily non-small cell lung cancer with EGFR mutation and metastatic colorectal cancer. Although the agents spare patients from typical side effects seen with more conventional cytotoxic chemotherapies, such as nausea or vomiting, they do have a unique side-effect profile, including potentially dose-limiting cutaneous toxicity. 

    March 11, 2021

    To discuss the information in this article with other oncology nurses, visit the ONS Communities.

    To report a content error, inaccuracy, or typo, email pubONSVoice@ons.org.

    Zac Pitts MSN, NP-C
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap

  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
    • © Copyright 2022 Oncology Nursing Society
     
    Back to Top ▲